Yuji Uehara, MD
@DrYujiUehara
Followers
341
Following
267
Media
61
Statuses
250
Medical Oncologist (National Cancer Center 🇯🇵)/ Precision medicine, Lung cancer, Early drug development/ JSMO social media committee
Tokyo, Japan
Joined April 2023
Don't wanna be here?
Send us removal request.
Explore trending content on Musk Viewer
My World
• 164770 Tweets
Into the Depth with YUTA
• 36615 Tweets
渋沢栄一
• 35028 Tweets
スーパーヒーロー
• 16387 Tweets
TEN FIREWORK IT
• 16087 Tweets
Gセルフ
• 15187 Tweets
タリーズ
• 13022 Tweets
マックス
• 11035 Tweets
イグナイター
• 10290 Tweets
Pinned Tweet
Delighted to present my oral presentation on “Pan-Cancer Analysis of 4-1BB Transcriptome Expression and Its Impact on Outcome in Patients Treated with ICIs” in the Developmental and Precision Medicine session at
#ESMOAsia23
. Special thanks to
@Dr_R_Kurzrock
&
@myESMO
!
0
3
14
2023年の駒込病院
@komagome_tmhp
の最優秀英文論文賞を受賞しました。駒込病院、NCCには感謝の気持ちで一杯です。戸井院長のお言葉のように、論文はIF 20辺りに壁があると感じますが、4月以降は、ワクワクして、長期的に患者さんと社会に貢献できる、本質的な研究へシフトしていきたいです！
0
3
76
🔥 HOT OFF THE PRESS from our study
@JTOonline
: the timing of ICI infusions may affect survival in locally advanced NSCLC patients. Early infusions lead to better outcomes than late ones. A first look at ICI chrono-modulation in non-metastatic cancers. 🕒
0
10
29
JSMO大学で医学生向けに作成した腫瘍内科医の紹介動画です。SNS-WGの一員として、本動画作成WGに関わらせて頂きました。砂川先生中心に多くの議論を経て良い動画が出来上がったと思うので、多くの人に見て欲しいです！
1
7
23
🚀 Exciting news! Building on our research (JAMA Netw Open), National Cancer Center Hospital, Chugai Pharma, Osaka Medical and Pharmaceutical University, & MICIN launched Japan's first company-sponsored Phase I oncology decentralized clinical trial.
2
4
18
Fantastic talk with Dr.
@DoctorJSpicer
& Dr. Maqueda on preoperative RWD cases in Canada. Incredibly insightful for thoracic surgeons and medical oncologists. Honoured to meet you both!
@haigan_geka
1
5
15
中外創薬科学財団の2024年度奨学金を受賞しました。4月からの本庄国際奨学財団 と重複受給になるため、辞退しますが、今までやってきた研究の方向性や努力が認められたことは、とても嬉しいです。国立がん研究センター、駒込病院、医科歯科の関係者には感謝申し上げます。
1
0
15
4月からの本庄国際奨学財団の28期奨学生（日本人国内大学院生）に選ばれました。毎年、60倍程度の倍率で、国立がん研究センター東・中央病院、駒込病院、医科歯科の様々な先生方のご指導とご支援の賜物で、感謝いたします。
1
0
12
@shinkato_unagi
@LargeRicefields
リード数が少ない場合、splice donor siteに近いhomopolymeric site (TTTT)のエラーが、誤ってex14 skippingのmutationsやindelとcallされたみたいです。先生のご指摘の通り、exon14 skip の偽陽性は珍しい事象なので、肺癌で一番権威のある雑誌に詳細が掲載されています。
1
0
10
腫瘍内科医はこうあるべき！みたいに学生時代は思っていましたが、本当はそうでなくて、がん患者さんのためというマインドセットのもと、色んな道や役割があって、その多様性が腫瘍内科医の魅力であることを本動画で伝えたいです。(この動画で紹介しきれないキャリアも含めて)
0
0
8
書かれていない点として、公用語に英語がない理由も大きい思います。依頼者➔大量の書類を何でも翻訳で時間↑/コスト↑、実施機関➔様々な書類/会議が英語のせいで多くの業務が医師に集中。効率↓ RT 「治験後進国」日本 世界の新薬の７割が使えず- 日本経済新聞
0
2
9
とても勉強になります。OncologyのRCTのpost hoc analysisで、HTEを見かけない(これから？)という疑問を持っているのですが、圧倒的にbiologyありきで、data-drivenの解釈が馴染みにくからでしょうか？JAMAの個別化治療の論文について｜
@GtoDr
1
0
9
Thrilled to announce that I've been awarded a grant by Chugai Pharma as a PhD candidate! It's an honor to receive this prestigious support, and I'm incredibly grateful for the opportunity.
0
0
8
Exploring De Novo EGFR T790M in NSCLC🇨🇳:
・Found in ~1% of NSCLC.
・ Coexists with L858R mutation ➔ 🔽 outcomes with 3rd-gen TKIs.
・Alone, de novo T790M's oncogenicity is limited, but increases with common EGFR mutation. What's its mechanistic role ? 🤔
0
2
7
Key findings on EGFR T790M carriers:
・> 50% diagnosed with lung cancer by 60.
・Lung nodules common in non-cancer patients.
・They often have somatic EGFR mutations.
・Study lacked Asian participants; more research needed.
・EGFR-TKI might be a risk-reducing strategy.
0
25
63
0
3
6
Wow, the NCI is exploring both ImmunoMATCH and ComboMATCH! In my opinion, we should make use of not just in vitro data but also human studies like I-PREDICT or OmniSeq analysis led by
@Dr_R_Kurzrock
to select drug combinations.
"The New NCI Precision Medicine Trials" - just published in
@CCR_AACR
on the latest precision medicine efforts
@theNCI
.
You can read about these 2nd generation precision medicine trials - ComboMATCH, iMATCH, and myeloMATCH - here:
#CancerResearch
#NCTN
0
13
17
0
1
6
@m0370
取り上げて頂き、ありがとうございます。多くの交絡因子や出版バイアスがありますが、今回の結果は自分達も驚いていて、過去の同様の報告や基礎的な面も併せると、免疫治療のchronotherapy を再考する余地は大きいと思っています。同テーマのTR研究は欧米のグループがもうすぐ論文に出すようです。
0
1
6
Our research, published in
@JAMANetworkOpen
, was featured in The ASCO Post News—a great honor. We found that longer travel times reduced the likelihood of patients participating in genotype-matched trials. via
@ascopost
0
3
5
Sotorasib, the Poster Child for Project Optimus: Truths & Fantasies 🧐. Outside the US, given PK, efficacy, cost (national health insurance) & toxicity, opting for 240mg seems a wise choice 💡. A single 960mg ($21,000/mo) prescription could last 4 months.
1
0
5
Very Important research by Dr.
@mollylisc
from 🇭🇰: Recurrent ILD 🫁 risk higher with Osi rechallenge (63%) vs. erlotinib (11%). Clinically Relevant for 🇯🇵 pts. Erlotinib suggested for Osi-induced ILD.
@JTOonline
1
0
5
The cost of 3.5-year recent cancer drugs ($700,000) is approximately half of the average lifetime salary in Japan. It’s unsustainable for our national health care system to provide these novel drugs to all patients. Younger generations will bear the burden.
Findings of this study indicate that the median annual price of anticancer drugs in the US is not associated with the novelty of their mechanism of action.
0
7
13
0
0
4
本日、私が今年の主幹事を務める筑駒医師の会の引き継ぎがありました。大学、がんセンター、海外どこ行っても、活躍しているOBが沢山います！創立20周年かつ1000人近いコミュニティになっていますが、もっと内部の繋がりを強くして、ITやバイオ系とのコミュニティとも繋がってもいければと思います。
0
0
5
@yusuke_mazda
強く同意します。日本臨床腫瘍学会のsns委員会をやっているのですが、そこの違いが大きな根底にあって「学会の写真解禁、SNS投稿」もなかなか進まなかったり、海外学会同様のことを行う障壁になっている感じています(投稿の責任の所在と連絡先が不明)。
0
3
4
とてもまとまっていて、勉強になります。本邦の学会でもSNS投稿解禁が増えてきて、必読と思います！学会のSNS-WGに複数関わっていますが、学会が色々細かいルールを決めるより、会員一人一人が自身の責任で著作権を勉強することが大事に思います。
0
0
5
@DrewMoghanaki
@dramycummings
@n8pennell
@DoctorJSpicer
@FordePatrick
@charlesrudin
@JieDengMDPhD
@StephenVLiu
Thank you so much for taking an interest in our study! Despite confounding factors and potential publication bias, the consistent findings from basic and clinical research make exploring the mechanism of ICI chronotherapy a worthwhile endeavor.🔍🕰️
0
1
4
The abstract, "Pan-cancer analysis of 4-1BB transcriptome expression and its impact on outcomes with ICIs," was chosen for a mini-oral and ESMO Asia travel grant. Thrilled! Huge thanks for the incredible opportunity and support
@Dr_R_Kurzrock
@OmniSeq
@zacksurg
@jacobadashek
0
2
5
A new WHO🌍 report reveals lung cancer as the top global cancer (2.5M new cases 📈) & leading in deaths (1.8M📈). Notably, it's the 2nd most common cancer among women👩 in both cases & deaths. A lesser-known fact many are unaware of.
#lungcancer
#LCSM
0
2
4
🔍 The cfDNA & multitarget stool DNA tests in NEJM are buzzing topics! While sensitivity for precancerous lesions is low, tech brilliance 🧠 will solve this challenge. Should this breakthrough hit lung cancers, how to intervene with premalignancy becomes crucial for patients.🫁
Hot off the press! “Multi-omics” approach (genomics, epigenomics, proteomics) to plasma testing proves effective in colorectal cancer screening. Hoping same will be seen in other cancer types
@NEJM
@ASCO
@isliquidbiopsy
3
69
214
1
0
3
490 NSCLC pts in NGS Testing at Tempus Labs.🧬 Variant Concordance: 66%. Unique variants: 29% found in tissue, 5% in ctDNA➡️Most assay-unique variants (>70%) detected by tissue testing. 📌Tissue is Still the issue in NSCLC!
@JAMANetworkOpen
0
1
3
My colleague, Dr. Kato from National Cancer Center Hospital East, will discuss the efficacy of ICI+chemo doublet vs. chemo for HER2-mutant NSCLC (268 pts) at LC-SCRUM Asia (15,251 pts). He'll address a crucial question 🤔: the optimal 1st-line Tx for HER2-mutant NSCLC.
#JSMO2024
0
0
3
🎉 Excited to share I've been selected for the Honjo International Scholarship Foundation's 28th cohort!! With a 1 in 60 acceptance rate, it's a prestigious honor. Huge thanks to the National Cancer Center, Komagome Hospital, and TMDU for their support.
0
0
4
⭐️JSMO2024 Early Career Oncologist Lounge
@JSMO_official
📣You can meet Dr. Lynn M. Schuchter
@ASCOPres
, President ASCO
@ASCO
, to ask questions, network, and receive career advice in the field of oncology.
🗓️Feb 23, 11:30～12:30
#JSMO2024
0
3
5
@shinkato_unagi
De novo, Acquired共にMET AMPに関しては1.有効性の問題と2.MET AMPのcut off がはっきしてない問題だと思います。MET exon 14 skippingはORR 40-60%あるのに、MET AMPは1st lineからORR 20-30%程度ですので、1・2共にまだ改善の余地が大きいと思います。
1
1
4
My twin brother, a researcher in Dr. Aviv Regev's Lab at Genentech (gRED) 🧬, is seeking a summer research intern. 🌟 There are numerous opportunities for top journal publications, combining AI with biology/medicine for drug discovery 🧪
0
0
3
🔬Research from the Breast TRACERx study on TNBC 🎀reveals that chromosomal instability🧬 (marked by a high frequency of LOH and WGD) leads to diverse subclones and immune evasion through mechanisms like HLA LOH and ecDNA-driven immune suppression.
@AACR
0
0
3
The RAGNAR study underscores the clinical benefits of selective FGFR inhibitors in a tumor-agnostic context, yet the ORR remains at 30%. Our findings
@Dr_R_Kurzrock
@jacobadashek
suggest that targeting co-alterations, such as FGFR and CDK4/6, could potentially enhance efficacy.
NEW: In the RAGNAR single-arm ph2 trial of erdafitinib in pts w/ adv solid tumours with FGFR alterations, an objective response was seen in 64 (30% [95% CI 24–36]) of 217 patients across 16 distinct tumour types (median FU 17·9 months [IQR 13·6–23·9]).
0
15
28
0
2
4
JSMOのメンバーとして、参加しましたが、とても良いイベントでした！日頃、交流の少ない地域や他分野の先生方から色々なアイディアやアドバイスを頂き、夜は理事長達や一線で活躍されている研究者と、夜遅くまで語り合う熱いイベントでした🔥これからも続いてほしいです。
@JSMO_official
@jcaopl
0
0
4
Abstract titles for
#ASCO23
released
@ASCO
Will be presenting a poster on our data from
@NccriOfficial
on "Impact of patient travel time on disparities in precision oncology clinical trials."
I'm excited to attend the annual meeting in Chicago!
0
0
3
I just rewatched Chris Abbosh's keynote lecture on Molecular Minimal Residual Disease and Early Detection. The concept of combo of ctDNA and pCR status, as well as TNM(B) staging, is very insightful.
#ASCOBT23
0
0
3
@m0370
FDA は患者さんに早く薬を届けるために、1. Phase 1/2有効性でaccelerated approva l→ 2. Phase 3 or 長期フォローで後にtraditional approvalなので、逆に後者の承認を受けた希少ドライバーへの分子標的薬は今までRETぐらいで、殆ど無いと思います！(それにMETが加わった)
0
0
2
@shinkato_unagi
@LTK81872901
横から失礼します。連携施設からCGP紹介後（国がん中央の我々の研究）では、「併存疾患、治療中、PS不良」が治験を提案できない理由になります。
その前の段階では、ご指摘のとおり、病勢進行・地理的要因がより上位にランクすると考えており、後者は大きな課題だと思います。
1
1
3
Methylation subtypes reveal cell origin and tumor phenotype. Using them as MRD markers, we could pinpoint SCLC transformation or recurrence sites.
Online Now: Integrative multi-omic cancer profiling reveals DNA methylation patterns associated with therapeutic vulnerability and cell-of-origin
0
43
160
0
0
2
Great summary of MCED: Over half of the patients with positive results in recent studies had no discernible cancer, yet they faced numerous risks of diagnostic procedures. This highlights a significant unmet need in MCED.
@ASCO
Daily News
0
0
2
Must read for young physician-scientist. "Young investigators in particular might have the greatest impact probing deeply Check for updates nature cancerTurning points where there is space to grow. Even graveyards, left fallow, can be fertile fields."
0
0
1
Why Osaka Medical and Pharmaceutical University (OMPU) is chosen as a satellite🏥? Find out in our prior paper. With a travel time of over 2 hours from OMPU (Osaka) to NCCH (Tokyo), Decentralized Clinical Trials could significantly reduce travel burdens.
0
1
3
@StephenVLiu
Thank you so much for tweeting about our study! Although there are many confounding factors and potential publication bias, it's worthwhile to investigate the mechanism of ICI chronotherapy.
0
0
3
Check out our editorial on ICI therapy for fusion-positive NSCLC (IMMUNOTARGET registry). It highlights the ineffectiveness of ICI in ALK/RET/ROS1 fusions and emphasizes the importance of accurate diagnostic methods for these rare subsets to avoid false positives by IHC or FISH.
0
0
1
Reflex testing has boosted the success rate of DNA tissue-based molecular testing 🫁. Japan lacks such a system, requiring oncologists to manually order tests via paperwork each time. We need the system to ensure Right drug-Right patient-Right time.
#LCSM
0
0
1
🔥🚨Hot off the press👉Increased travel time was associated with a reduced chance of genotype-matched trial participation after CGP testing. 👉Regional disparities in precision oncology👉Need for solutions like DCT to ease the travel burden.
Longer travel times were associated with a decreased likelihood of participation in genotype-matched trials. Regional disparities perpetuate inequities in
#PrecisionOncology
.
@DrYujiUehara
@NccriOfficial
0
1
2
0
0
2
In the upcoming NCI-ComboMATCH trial, combinations are limited to 'targeted therapies'. While I concur with the importance of exploring combinations with immunotherapies, I'm concerned about potential toxicity variations across different tumor types.
The NCI-MATCH trial: lessons for precision oncology
@NatureMedicine
👏Very innovative
👉1,593/6,000 pts assigned to 38 subtrials
👍pos. signal in 7/27 subtrials
👉Proof of concept > we need to continue this pass to improve outcome & tackle 💊resistance
5
37
88
0
1
2
@slimshady__7
ですよね。グローバルへのインパクトもないでしょうし。。最近、中国も髄膜転移に対して、オシメルチニブ倍量をretrospectiveでまとめたstudyを出していましたよね。日本は用量を下げる試験は進む一方、用量を上げるような試験は聞いたことないんですが、何かありましたっけ？
1
0
1
Due to a high treatment-related death rate (7.4%, n = 11/148) in an early-terminated trial, Japanese oncologists are wary of using the 9LA regimen (platinum-doublet 2 cycles with nivolumab + ipilimumab) for metastatic lung cancer.
Interesting letter to the editor
@Annals_Oncology
reports high rate of cytokine release syndrome
#CRS
and irAEs with nivolumab + ipilimumab for NSCLC in Japan. JCOG2007 trial stopped for high rate of treatment-related deaths. Pharmacogenomic differences?
0
13
36
0
0
2
Healio has featured our study! We're honored to have our work recognized in the US medical media. "Travel time linked to participation in genotype-matched cancer trials "
@GoHealio
1
0
2
Read our editorial on BRAF RNA expression in lung adenocarcinoma. Approximately 75% of LUAD patients displayed 🔼 BRAF RNA expression, correlating with 🔽 prognosis to platinum doublet therapy. A deeper grasp of RNA expression beyond DNA is needed.
0
0
1
@mollylisc
@JTOonline
In our institution, we frequently transition from Osi to Afa or Gefi because we experience a higher incidence of severe ILD associated with the Osi rechallenge. This anecdotal evidence is confirmed in your paper!!
0
0
1
@nextommysuke
@slimshady__7
約60%のプロトコール内のクロスオーバーに加えて、15%はプロトコール外で、selective RET inhibitorをtrial外で使ってる記載があるので、68人の中で75% (51人くらい？)と比較的高いクロスオーバー割合だと思います。残りは先生方のおっしゃる通り、有害事象や脳転移によるPS低下とかでしょうか。
1
0
2
Just out! We reported the successful treatment of ALK+ LCNEC with sequential ALK inhibitors. Emphasizing the importance of NGS for LCNEC patients, especially younger patients.
#LCSM
@JTOonline
0
0
1
Kudos to our department for this exceptional research demonstrating the importance of the genomic screening project in Asia (LC-SCRUM Asia).
Data from LC-SCRUM-Asia
@JTOonline
describes
#BRAF
mutant NSCLC. Overall, 3.5% had a BRAF mutation (30% of which were class 1: V600E). mPFS with chemotherapy 11.5m and mOS 34.8m. Non-V600E mutations were more common in this Asian cohort.
0
8
30
0
0
2
Physician motivation and knowledge gaps between referring and early drug development doctors are significant barriers to enrollment. We need a system to identify and prioritize patients for referral.
Molecular targeted trial w/identified potentially eligible patients within feasible distance failed to enroll; findings raise the hypothesis that the biggest barrier to enrollment is motivation of treating physicians.
2
7
16
0
0
1
4月からは国立がん研究センターがん進展研究分野の吉田健一先生のLabで、肺の前がん病変〜正常組織の研究を行います。将来的には、非喫煙者の肺がん根治を目指して、前がん病変段階からの個別化介入を目指したいと考えています。（腫瘍内科専門医のトレーニングは継続します）
0
0
2
@akihiro_ohba
@MamMa_mimumemo
大場先生 ありがとうございます。勝手ながら、いつも国際的なご活躍拝見してて、尊敬してて、やる気をもらっています。JSMOがアジアで一番の学会を目指すには、ASCO/ESMO同様のSNS活動盛り上げが必須と考えています。よろしくお願いします！
0
0
2
🔍 Interesting study: The number of ctDNA mutations, plasma DNA concentration, and clinical factors can predict outcomes in RRMM. TP53 mutation has different meanings between BMPC and ctDNA. We may say the same thing in the lung cancer space. 🫁
Happy to share our latest paper from
@BloodJournal
.
@yasunori_kogure
and colleagues analyzed relapsed/refractory
#multiple_myeloma
(RRMM) and found that molecular profiling with
#ctDNA
mutations can enhance patient management strategies for RRMM.
2
5
14
0
0
1
Insightful summary on cancer screening status. PATHFINDER study shows MCED test detected cancer in 1.4% of 6,621 people, but only 38% of positives were confirmed - a high false-positive rate. Much work needed for clinical implementation."
Clinical trials assess a precision-medicine approach to cancer screening.
News feature from
@sofiamoutinhoBR
, part of our focus on Building Healthy Populations.
0
8
29
0
0
0
Just found out my high school classmate authored this paper. Incredible!
News and Views:
@masakanai
explains how fine-scale population structures can unveil crucial insights into healthcare disparities. Part of our focus on Building Healthy Populations.
@broadinstitute
@MGH_RI
0
1
15
0
0
1
Early-Stage Lung Cancer: Using Circulating Tumor DNA to Get Personal. .
・Two ways: Tumor-informed (NGS) vs. Tumor-agnostic (DNA methylation, cfDNA fragmentation).
・ Most NSCLC studies used the former way.
・ Main issue: Low negative predictive value.
0
0
1
大きく分けてDBの信頼性は1. 治験統合DB>2. 臨床試験統合DB/薬事承認レジストリー>3. 前向きレジストリー>4. カルテデータで、自分が使用しているDBは1.はCSDR、2.は日本肺癌学会のJIDB、3. LC-SCRUMですが、解析実務者と解析立案者のブラインドが正しいのか？ジレンマは常に感じます。
1
0
1
Must read on the integration of AI and conventional statistical methods. Many formats of protocols focus solely on conventional stats, which can be frustrating sometimes. 'Where Medical Statistics Meets Artificial Intelligence' | NEJM "
0
0
0
@mollylisc
@JTOonline
Kudos to you!! I hope we can collaborate in the future. Please let me know if you need a cohort from Japan!
1
0
1
Facing hurdles in MCED🩸: 1️⃣ Blood sampling skews towards hematologic cancer signals. 2️⃣ Most detected solid tumors: late-stage or recurrent. 3️⃣ Many positive results, but no identified cancer. 4️⃣ Only <1/3 of cancers diagnosed were detected by MCED.
0
0
0
@M_Torasawa
言及、ありがとうございます。これは知らなかったです。皆、自分の詳しくない研究分野があると思いますので、スクリーニングやインプットスピードを上げることに、とても役立ちますね！
0
0
1
Men face a higher risk of lung cancer from household PM2.5 exposure than women, including in Asia. Last year,
@CharlesSwanton
reported the link between PM2.5 and EGFRm NSCLC. Yet, unknown factors may increase women's risk for this cancer
@JTOonline
#LCSM
1
0
1
@stephanieplsaw
@danieltanmd
Congratulations on your paper! The focus on not only MRD but also accessibility is excellent, and the findings are highly relevant to many Asian countries!! Is monitoring tumor markers a common practice in SG? (It's a standard in Japan.)
1
0
1
@waraonc23jp
全然、先生には及ばないですが、ありがとうございます。全体的な日本の研究環境や研究の価値の低下は止まらないと思うので、自分の領域では 1. 国際的に、2. 重要かつ面白いクエッション、3. スピード感で工夫していけたらと思っています！また色々ご指導頂けると幸いです。
1
0
1
@slimshady__7
まとめ、ありがとうございます。ALINAの日本人subsetはdose reductionが多かったとの噂も聞きましたが、こういう研究見ると、日本だけadjuvant settingでは600 mg BID, metastatic settingでは300 mg BIDみたいな逆バージョンの良く分からない状態になることを懸念しています。。
1
0
0
🔬Outstanding paper: In allogeneic CAR T cells, 3 genes were silenced via base editing:
1. T-cell receptor β chain: Reduces T-cell receptor expression & graft-versus-host effect.
2. CD52: Enables anti-CD52 immunosuppression.
3. CD7: Targets only tumors, not CAR T cells themselves
Original Article: Base-Edited CAR7 T Cells for Relapsed T-Cell Acute Lymphoblastic Leukemia
Science behind the Study: Engineering CAR T Cells for Off-the-Shelf Use
0
21
59
0
0
0
@M_Torasawa
二極化は駒込とNCCEもそうですね！NCCEは別の独自ファクターを提供できる気もします笑 同時発表は、先生ならすぐだと思うのですが、そのお気持ち分かります😆 一方で、ASCOで採択されて、その反響も含めて、より良い雑誌に引っ掛かったということもありそうですよね🤔
0
0
1
@waraonc23
Sure. Looking forward to seeing your IDO1 poster!! Actually, I'm working on a similar project targeting 4-1BB with Dr.Kato.
0
0
1
@shinkato_unagi
ご指摘のように、EGFR患者のTKI後のMET AMPに対するMET inhibitorsがORR 30-40%で、現状は一番可能性あると思います！といっても、肺がん領域で単armで承認するほどの有効性とは言えず、mPFSも5ヶ月程度で標準療法のプラチナ併用療法に勝てるか怪しく、有効性・カットオフ共に課題ありだと思います。
1
0
1
@herbloong
@JSMO_official
@ToshioShim1025
@apoddc
Thanks a lot for your excellent talk!! It was a pleasure meeting you, and I'm so happy to see you enjoying the misonikomi udon😆. Let’s keep in touch.
0
0
1
@waraonc23jp
外来通院する体力がない患者さんは、抗がん剤の適応がないのが原則だと思いますので、本来はそうあるべきですよね��普通に入院でもできるとなると、通院や介護負担の面で患者/家族には良い面もあると思いますが、最初の前提が疎かな状態で抗がん剤が使用されてるのではと感じるときもあります。
0
0
1
@m0370
そのaccelerated とtraditional approvalsの線引きは、恣意的な部分とも思います。肺癌の分子標的薬��accelerated approvalsを企業が撤回する/FDAにさせられる例は少なそうですが、武田のEGFR exon20挿入mobocertinibみたいな撤回例もあり、皆保険制度では難しそうですよね。
0
0
0
今日は本セミナーを聴講しました。薬事利用のDB活用に当たり、臨床家/統計家/規制当局かの第一人者から、統計から実務的な話まで詳細に聞けて、非常に勉強になりました。私も詳細は知らなかったのですが、身近に先進的な取り組みをやってる機会に触れられるのが国がん研修の魅力だと思います。
2
0
1
@waraonc23jp
ありがとうございます。先生のご投稿、とても勉強になると共に刺激になっています。今年のASCOも出したので、もし採択されたらまた直接お会いしたいです！よろしくお願いします。
1
0
1
@RIHigashiyama
それはOKなはずですが、それすら日本の学会はグレーな雰囲気ですよね。著作権、肖像権、抄録/スライド権利承諾の問題、問題が起こった時の責任所在など、細かい点で色々詰めるところはあるのですが、今やってるJSMO SNS-WGとしてはASCO/ESMO同様の全面解禁に全力で動いてます！
0
0
1